Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders

被引：0
|
作者：
Vakkalanka, Swaroop [1 ]
Merikapudi, Gayatriswaroop [2 ]
Babu, G. [2 ]
Routhu, Kasiviswanath [3 ]
Veeraraghavan, Sridhar [4 ]
Viswanadha, Srikant [5 ]
机构：
[1] Rhizen Pharmaceut SA, Gen Adm, La Chaux De Fonds, Switzerland
[2] Incozen Therapeut Pvt Ltd, Med Chem, Hyderabad, Andhra Pradesh, India
[3] Incozen Therapeut Pvt Ltd, Pharmacol, Hyderabad, Andhra Pradesh, India
[4] Incozen Therapeut Pvt Ltd, Pharmacokinet, Hyderabad, Andhra Pradesh, India
[5] Incozen Therapeut Pvt Ltd, Drug Discovery, Hyderabad, Andhra Pradesh, India
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
Allergy; Anti-inflammatory; Immunology;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
1050
引用
收藏
页数：1
相关论文
共 20 条
  • [1] Pharmacodynamic evaluation of RP3128, a novel and potent CRAC channel inhibitor in guinea pig models of allergic asthma
    Sutovska, Martina
    Kocmalova, Michaela
    Franova, Sona
    Vakkalanka, Swaroop
    Viswanadha, Srikant
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2016, 772 : 62 - 70
  • [2] Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells
    Viswanadha, Srikant
    Cortijo, Julio
    Milara, Javier
    Vakkalanka, Swaroop
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [3] RP-3500: A novel, potent and selective ATR inhibitor that is effective in pre-clinical models as a monotherapy and in combination with PARP inhibitors
    Roulston, Anne
    Zimmerman, Michal
    Papp, Robert
    Skeldon, Alex
    Pellerin, Charles
    Dumas-Berube, Emilie
    Dumais, Valerie
    Dorich, Stephane
    Fournier, Sara
    Li, Li
    Leclaire, Marie-Eve
    Yin, Shou Yun
    Chefson, Amandine
    Alam, Hunain
    Yang, William
    Fugere-Desjardins, Chloe
    Hammond, Sabrina
    Skorey, Kathryn
    Mulani, Amina
    Rimkunas, Victoria
    Veloso, Artur
    Hamel, Martine
    Stocco, Rino
    Mamane, Yael
    Li, Zuomei
    Young, Jordan
    Zinda, Mike
    Black, Cameron
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [4] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Pierre, Fabrice
    Chua, Peter C.
    O'Brien, Sean E.
    Siddiqui-Jain, Adam
    Bourbon, Pauline
    Haddach, Mustapha
    Michaux, Jerome
    Nagasawa, Johnny
    Schwaebe, Michael K.
    Stefan, Eric
    Vialettes, Anne
    Whitten, Jeffrey P.
    Chen, Ta Kung
    Darjania, Levan
    Stansfield, Ryan
    Bliesath, Joshua
    Drygin, Denis
    Ho, Caroline
    Omori, May
    Proffitt, Chris
    Streiner, Nicole
    Rice, William G.
    Ryckman, David M.
    Anderes, Kenna
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2011, 356 (1-2) : 37 - 43
  • [5] Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer
    Fabrice Pierre
    Peter C. Chua
    Sean E. O’Brien
    Adam Siddiqui-Jain
    Pauline Bourbon
    Mustapha Haddach
    Jerome Michaux
    Johnny Nagasawa
    Michael K. Schwaebe
    Eric Stefan
    Anne Vialettes
    Jeffrey P. Whitten
    Ta Kung Chen
    Levan Darjania
    Ryan Stansfield
    Joshua Bliesath
    Denis Drygin
    Caroline Ho
    May Omori
    Chris Proffitt
    Nicole Streiner
    William G. Rice
    David M. Ryckman
    Kenna Anderes
    Molecular and Cellular Biochemistry, 2011, 356 : 37 - 43
  • [6] Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models
    Stefka, Andrew
    Johnson, David
    Rosebeck, Shaun
    Park, Jae-Hyun
    Nakamura, Yusuke
    Jakubowiak, Andrzej J.
    BLOOD, 2017, 130
  • [7] Pre-Clinical Development of a Novel, Potent and Selective BTK Inhibitor for Autoimmune Disease and Inflammation Including Arthritis
    Morris, Stephen
    Laurent, Alain
    Jerome, Lori
    Boudreault, Alain
    Ashdown, Helen
    Rose, Yannick
    Bureau, Patrick
    Yin, Shou-Yun
    Cleroux, Patrick
    Labit, Delphine
    Henry, Nicholas
    Tremblay, Marie-Noelle
    Guerard, Marlyna
    Berube, Emilie Dumas
    Spathis, Kosta
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Potent activity of a novel, irreversible inhibitor of the ubiquitin-proteasome pathway against pre-clinical models of multiple myeloma.
    Kuhn, DJ
    Voorhees, PM
    Strader, JS
    Shenk, KD
    Sun, CM
    Demo, SD
    Bennett, MK
    Orlowski, RZ
    BLOOD, 2005, 106 (11) : 452A - 452A
  • [9] Pre-clinical study of SYX3759, a novel PARG inhibitor for the treatment of homologous recombination deficient malignancies
    Tang, Xuzhen
    Cui, Yaqi
    Zhang, Lanqiao
    Jin, Huihui
    Xu, Zeqiong
    He, Hu
    Ge, Chongxun
    Liu, Song
    Yu, Xiaochun
    Shi, Song
    CANCER RESEARCH, 2023, 83 (07)
  • [10] NOVEL KCNQ2/3 CHANNEL OPENER WITH IMPROVED POTENCY AND CHANNEL SELECTIVITY AS A POTENTIAL NEW TREATMENT FOR PARTIAL-ONSET SEIZURES: PRE-CLINICAL CHARACTERIZATION
    Furuya, T.
    Purohit, A.
    Edwards, S.
    EPILEPSIA, 2013, 54 : 177 - 177
12